Archives
- 2018-07
- 2019-06
- 2019-07
- 2019-08
- 2019-09
- 2019-10
- 2019-11
- 2019-12
- 2020-01
- 2020-02
- 2020-03
- 2020-04
- 2020-05
- 2020-06
- 2020-07
- 2020-08
- 2020-09
- 2020-10
- 2020-11
- 2020-12
- 2021-01
- 2021-02
- 2021-03
- 2021-04
- 2021-05
- 2021-06
- 2021-07
- 2021-08
- 2021-09
- 2021-10
- 2021-11
- 2021-12
- 2022-01
- 2022-02
- 2022-03
- 2022-04
- 2022-05
- 2022-06
- 2022-07
- 2022-08
- 2022-09
- 2022-10
- 2022-11
- 2022-12
- 2023-01
- 2023-02
- 2023-03
- 2023-04
- 2023-05
- 2023-06
- 2023-07
- 2023-08
- 2023-09
- 2023-10
- 2023-11
- 2023-12
- 2024-01
- 2024-02
- 2024-03
- 2024-04
- 2024-05
- 2024-06
- 2024-07
- 2024-08
- 2024-09
- 2024-10
- 2024-11
- 2024-12
- 2025-01
-
The major phase trial NCT enrolled participants with mild to
2024-06-13
The major phase 2 trial (NCT01343966) enrolled 431 participants with mild to moderate AD who received either low-dose SC crenezumab 300 mg or placebo biweekly (n = 184) or high-dose intravenous crenezumab 15 mg/kg or placebo every 4 weeks (n = 247) for 68 weeks 38, 40. No significant treatment benef
-
Inflammatory factors released by activated
2024-06-13
Inflammatory factors released by activated cells during AD are very important for the disease progression. Not only several inflammatory cytokines, such as IL-1β, IL-18, and IL-33, but also anti-inflammatory ones, as IL-10 and IL-13, are upregulated in the brain of AD patients (Morimoto et al., 2011
-
Since the publication of the guidelines data
2024-06-13
Since the publication of the 2011 guidelines, data have continued to accumulate indicating that the cognitive decline in AD occurs continuously over a long period [6–8], and that progression of biomarker measures is also a continuous process that begins before symptoms [9–14]. Thus, the disease is n
-
br Acknowledgements The authors would like to thank
2024-06-13
Acknowledgements The authors would like to thank Dr. Bradford B. Lowell for providing us with β-less and WT breeding pairs. Funding sources: This work was supported by NIH Grant DK028082 (to E.M.F) and by an Institutional Research Training Grant NRSA 5T32DK751627 (to N.D.). Introduction The e
-
The role of circulating physiologic concentrations of
2024-06-13
The role of circulating physiologic concentrations of FGF21 in glucose metabolism, however, remains unclear. Circulating FGF21 levels in obese and diabetic rodents, and in patients with type 2 diabetes are significantly higher than those in controls without diabetes [4], [5], [6]. On the other hand,
-
We observed PACAP immunoreactivity in the molecular layer of
2024-06-13
We observed PACAP2 immunoreactivity in the molecular layer of the cerebellar cortex in zebrafish. This result is consistent with the reporting of PACAP immunoreactivity in the soma and fibers of Purkinje cells and the presence of PACAP mRNA in the Purkinje-cell and granular-cell layers in rats [43].
-
The A b action occurs in conditions where high concentration
2024-06-13
The A2b action occurs in conditions where high concentrations of adenosine is generated, so its blockage does not interfere with other physiological processes mediated by adenosine and others AR [105]. Furthermore the A3 receptor was shown to have pro-apoptotic effects on tumor lines of breast, lung
-
droperidol B lymphocytes are found in blood lymph nodes sple
2024-06-13
B lymphocytes are found in blood, lymph nodes, spleen and tonsil and other mucosal tissues [110]. These cells originate in the bone marrow from a common progenitor shared with T, NK, and some DC subsets [111]. Progenitor droperidol progress through the early stages of maturation, rearranging heavy-
-
XL-888 The first natural product described as
2024-06-12
The first natural product described as 5-LO inhibitor was the polyphenol nordihydroguaiaretic XL-888 from the Mexican dessert plant Larrea divaricata in 1981 (Bokoch and Reed, 1981), short after the initial identification of 5-LO in 1979 (Borgeat and Samuelsson, 1979). Long time before mPGES-1 was
-
MS436 br Introduction S http www apexbt com media
2024-06-12
Introduction Systemic lupus erythematosus (SLE) is a group of systemic autoimmune disorders characterized by anti-nuclear MS436 (ANA), rashes and photosensitivity, joint inflammation, nephritis, and other clinical criteria. SLE develops through the breakdown of three major checkpoints: adaptive
-
The molecular mechanisms involved in the
2024-06-12
The molecular mechanisms involved in the pathogenesis of cholestatic pruritus remain unknown [45], [46]. Indeed, there has been an enormous effort at understanding the etiology of PBC-related pruritus, including work at the cellular and molecular level, but such efforts have not been translated int
-
br Materials and methods br Results br
2024-06-12
Materials and methods Results Discussion Despite the relative complexity of immunotherapy, such treatment may have an important role, in conjunction with other therapies in the treatment of cancer refractory to conventional treatments alone. Clinical studies have recently shown that adding
-
Maynard et al demonstrated that serum levels
2024-06-12
Maynard et al. [54] demonstrated that serum levels of sFlt-1 were five times higher in pregnant women with PE than in normotensive women; as a consequence, VEGF and PlGF levels were found to be proportionally reduced in these women [54]. The literature confirms that there is a sharp increase in sFlt
-
br Material and methods br Results
2024-06-12
Material and methods Results Discussion Nimodipine administration inhibited the level of AMP-activated protein kinase (AMPK) phosphorylation, a sensor of cellular energy status that directs metabolic SIN-1 chloride receptor to support cellular growth and survival. CCH influences the oxygen
-
br Results The newly synthesized leucine
2024-06-12
Results The newly synthesized leucine ureido derivatives were firstly evaluated for their enzymatic inhibition using porcine kidney APN (Microsomal, Biocol) with bestatin as the positive control (Table 1). One isoleucine ureido derivative 14 and phenylglycine ureido derivative 15 were also synth
14432 records 105/963 page Previous Next First page 上5页 101102103104105 下5页 Last page